Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
Neeltje SteeghsCarlos Alberto Gomez RocaKristoffer Staal RohrbergMorten Mau SorensenDebbie G J RobbrechtJosep TaberneroSamreen AhmedMaria E Rodríguez-RuizCaroline ArdeshirDaniela SchmidNassim SleimanCarl WatsonHanna Piper-LepoutreDavid DejardinStefan EversChristophe BoetschJehad CharoVolker TeichgräberIgnacio Melero BermejoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
FAP-IL2v had a manageable safety profile and showed initial signs of antitumor activity in advanced/metastatic solid tumors.